Market Overview

UPDATE: Oppenheimer Upgraded Lannett Company and Set PT

Share:
Related LCI
A Peek Into The Markets: U.S. Stock Futures Signal Lower Start On Wall Street
Despite Department Of Justice Investigation, Now May Be The Time To Buy Generic Drug Stocks
Is 'Value' Alive And Well? Let's Ask The '29.9% In 9 Months' Portfolio... (Seeking Alpha)

Oppenheimer analyst Rohit Vanjani Upgraded Lannett (NYSE: LCI) from Perform to Outperform and set a $29 PT following Impax Labs price boost on generic digoxin.

Vanjani downgraded Lannett two days from Outperform to Perform and removed his $20 PT a mere two days ago. In Wednesday's note, the analyst cited the company's significant outperformance. Today's note focused on Oppenheimer's confidence that the LCI price boost won't be reverted as a competitor has followed suit. The $29 PT is $5 higher than Bloomberg's average PT data.

Lannet has quadrupled Year to Date versus the Russell 2000 Health Care (RGUSHS) which is up 42 percent.

Lannett closed at $21.50 on Thursday and is currently trading +11.3 percent.

Latest Ratings for LCI

DateFirmActionFromTo
Aug 2016Raymond JamesMaintainsOutperform
Jun 2016Deutsche BankInitiates Coverage onHold
Mar 2016Canaccord GenuityDowngradesBuySell

View More Analyst Ratings for LCI
View the Latest Analyst Ratings

Posted-In: Oppenheimer Rohit VanjaniAnalyst Color Upgrades Price Target Analyst Ratings

 

Related Articles (LCI)

View Comments and Join the Discussion!